I think I may have posted this once before, not sure, but if I did, I didn't get the info I wanted, so trying one more time.
I had genomic testing done on my tumor, a proprietary test done at my Drs lab, looking at 4 data points.
It looks to me like I have some indicators of low probability of recurrence and some indicator of high chance (ERG) (which I went back to look at as a result of Yarbos post about
being metastatic). But I'm not sure.
Can anyone help me interpret this? Here is the text of the path report.....
COLLECTION DATE:
Surgical Pathology Report
SPECIMEN SOURCE:
A. ADDITIONAL REPORT [MS-15-00314]
CLINICAL HISTORY:
Prostate Cancer
DIAGNOSIS:
See MS-15-314 for diagnostic details
Precise MD -- Immunohistochemical Panel Prostate
Staining Staining
Antibody Frequency Intensity RESULTS
AR 70% 2-3+ POSITIVE
ERG 70% 3+ DIFFUSE OVEREXPRESSION
p53 1.0% 1+ NEGATIVE
ki-67 3.3% 3+ LOW PROLIFERATION
INTERPRETATION:
The moderately diffuse, moderate to high Androgen Receptor (AR;
2-3+, 70%) and low Ki67 (proliferative index: 3.3%) would suggest
that the patient is at low risk for disease progression.
In addition, the diffuse overexpression of ERG protein supports
the presence of the ERG rearrangement. The lack of p53 protein
supports the absence of a TP53 mutation.
1. Donovan et al., Personalized prediction of tumor response and
cancer progression on prosta
te needle biopsy. J Urol 2009;
182:125-32, 2. Svensson et al., A comparative study of ERG status
assessment on DNA, mRNA, and protein levels using unique samples
from a Swedish biopsy cohort. Appl Immunohistochem Mol Morphol
2014; 22:136-41.3). Kluth et al., Clinical significance of
different types of p53 gene alteration in surgically treated
prostate cancer. Int J Cancer 2014.
COMMENTS-
AR Negative < 1%, Weak Positive 1 - 10%, Positive > 10%
ERG Negative = <1%, Focal Overexpression 1 - 25%, Diffuse
Overexpression > 25%
p53 Negative < 5%, Borderline 5 - 10%, Positive >10 - 50%, Strong
Positive > 50%
Ki-67 High/Low Cutoff = 6.0% (Mayo Clin Proc
2014;89(3);308-318)
Block Examined- ms-15-314 A1
TECHNICAL NOTES-
For each antibody, a minimum of 500 tumor cells were counted.
All immunostains were performed on formalin-fixed,
paraffin-embedded tissue with appropriate controls on Ventana
Benchmark Ultra.
AR clone SP107, Rabbit monoclonal
ERG clone EPR3864,
Rabbit monoclonal
p53 clone DO-7, Mouse monoclonal
ki-67 clone 30-9, Rabbit monoclonal
Final Diagnosis performed by
G. KENNETH HAINES III, MD
Electronically signed 2/17/2017 5:59:41PM
Post Edited (Pratoman) : 3/31/2017 10:31:34 AM (GMT-6)